Create a free research account to view current pricing and place an order.
Mechanism of action
Melanotan II is a melanocortin receptor agonist with activity at melanocortin receptors involved in melanogenesis, appetite signaling, libido, and central melanocortin pathways.
Half-life & pharmacokinetics
Half-life: Short-to-moderate; context dependent.
Human pharmacokinetics are not standardized. Treat exposure as short acting unless compound-specific data or formal formulation labeling indicates otherwise.
Research dosing reference
250 mcg-1 mg daily or every other day depending on pigmentation/libido research context.
Dose interpretation (U-100 units)
| Target dose | U-100 units |
|---|---|
| 250 mcg | 5 units |
| 500 mcg | 10 units |
| 1 mg | 20 units |
Units are concentration-specific - confirm against your actual reconstitution volume.
Reconstitution & concentration
| Vial | Preferred reconstitution | Final concentration |
|---|---|---|
| 10 mg | 2 mL BAC Water | 0.050 mg/unit |
Injection timing
Often administered evening or consistent daily/EOD; UV exposure variables must be controlled in pigmentation research.
Beginner escalation
Begin very low due to nausea, flushing, libido, and pigmentation response variability.
Side-effect mitigation
Monitor nausea, flushing, appetite changes, libido changes, mole/pigment changes, and blood pressure response.
Stack compatibility
Avoid stacking with PT-141 or other melanocortin agents without careful dose separation and monitoring.
Storage & stability
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically.
Protocol duration & reassessment
Use short pigment-response blocks with regular skin/mole monitoring and off-intervals. Avoid indefinite use without dermatologic and tolerance review. Appendices Appendix A - GLP / Metabolic Pathway Primer GLP-1 is an incretin hormone released primarily from intestinal L-cells after nutrient exposure. GLP-1 receptor signaling enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and activates hypothalamic/brainstem satiety pathways. GIP is another incretin hormone that supports glucose-dependent insulin secretion and may influence adipocyte nutrient partitioning. Glucagon receptor agonism differs from GLP-only signaling: it may increase hepatic fatty-acid utilization and energy expenditure, which is why triple agonists are mechanistically distinct from standard GLP-1 agonists. Metabolic improvements seen with incretin-pathway compounds often reflect multiple overlapping mechanisms: reduced caloric intake, improved glycemic control, changes in hepatic glucose output, lower triglyceride flux, reduced ectopic fat burden, and secondary improvements in inflammatory markers. Appendix B - Protocol Duration Logic Protocol duration depends on use case. Acute repair protocols are usually short and objective-driven. Maintenance protocols are lower-frequency and reassessed periodically. Metabolic modulation may be long-term but still requires scheduled review. High-caution investigational compounds should not be repeated casually. Suggested reassessment categories: - Acute injury or repair: reassess 2-6 weeks. - Metabolic modulation: reassess 8-12 weeks. - GH-axis protocols: reassess 8-12 weeks with IGF-1/glucose context where appropriate. - Mitochondrial support: reassess 4-12 weeks. - Bioregulator pulses: reassess after 10-30 days and allow off-intervals. - High-caution investigational agents: extended reassessment intervals and clinician review strongly preferred. Appendix C - GH Axis Pathway Primer The GH axis is driven by hypothalamic-pituitary signaling. GHRH analogs stimulate pituitary GHRH receptors to promote endogenous GH pulses. GHSR/ghrelin receptor agonists can amplify GH secretory pulses but may also affect hunger, water retention, and glucose handling. Downstream IGF-1 signaling is biologically meaningful but requires monitoring because excessive GH-axis stacking can increase edema, tingling, glucose variability, and carpal-tunnel-like symptoms. Appendix D - Reconstitution Mathematics U-100 insulin syringes measure volume, not dose. On a U-100 syringe, 100 units equals 1.00 mL and 1 unit equals 0.01 mL. Dose per unit is calculated as total vial content divided by total units after reconstitution. Examples: 10 mg + 2 mL = 10 mg / 200 units = 0.050 mg/unit. 20 mg + 2 mL = 20 mg / 200 units = 0.100 mg/unit. 30 mg + 3 mL = 30 mg / 300 units = 0.100 mg/unit. 60 mg + 3 mL = 60 mg / 300 units = 0.200 mg/unit. This is why 20 units is not a dose by itself. 20 units of a 10 mg vial reconstituted with 2 mL equals 1 mg, while 20 units of a 60 mg vial reconstituted with 3 mL equals 4 mg. Appendix E - BAC Water vs AA Water vs Saline Bacteriostatic water contains benzyl alcohol and is commonly used for multi-dose peptide reconstitution when compatible with the compound. Sterile saline may improve comfort in some contexts but does not provide the same antimicrobial preservation. Acetic acid solution may improve stability or solubility for certain peptides, especially some IGF-style or difficult-to-solubilize compounds. DMSO or specialty solvents may be required for some formulation-sensitive compounds, but should never be assumed compatible without formulation review. Solvent selection affects stability, comfort, sterility, and concentration behavior. Copper-containing or high-content peptides often benefit from larger reconstitution volumes to improve dissolution and reduce injection discomfort. Appendix F - Storage, Stability, and Degradation Peptides can degrade through heat exposure, UV/light exposure, oxidation, hydrolysis, microbial contamination, repeated freeze/thaw cycles, and excessive agitation. Best practices include refrigerated storage after reconstitution, minimizing light and temperature cycling, gentle reconstitution instead of shaking, sterile handling, and avoiding repeated puncture beyond reasonable multi-dose handling windows. Lyophilized products are generally more stable than reconstituted products, but exact stability depends on peptide sequence, excipients, solvent, pH, and sterility conditions. Appendix G - Common Operational Mistakes Common mistakes include confusing units with milligrams, using protocols without knowing vial concentration, assuming a 20 mg vial and 60 mg vial dose the same at equal syringe marks, escalating too quickly, stacking overlapping incretin agonists, failing to hydrate during appetite-suppressive protocols, using the wrong solvent, shaking fragile peptides, and treating research-only compounds as standardized clinical products. The operating philosophy of this compendium is conservative: one change at a time, known concentration, clear objective, documented response, and escalation only when tolerated. Selected References and Evidence Notes 1. FDA Prescribing Information: Ozempic/Wegovy (semaglutide) - GLP-1 mechanism, half-life, Tmax, steady-state behavior. 2. FDA Prescribing Information: Mounjaro/Zepbound (tirzepatide) - GLP/GIP mechanism, pharmacokinetics, half-life, Tmax, and steady-state behavior. 3. FDA Prescribing Information: Egrifta/Egrifta WR (tesamorelin) - GHRH analog pharmacology, IGF-1 monitoring, and metabolic safety considerations. 4. FDA Prescribing Information: Vyleesi (bremelanotide/PT-141 analog) - melanocortin receptor agonism, Tmax, and terminal half-life. 5. BPC-157 literature: angiogenesis, nitric oxide signaling, VEGFR/Akt-eNOS pathway discussion, and tissue-repair research. 6. Thymosin beta-4 literature: actin-binding biology, angiogenesis, wound healing, and tissue repair. 7. Pickart et al. and related GHK-Cu reviews: copper peptide signaling, collagen remodeling, antioxidant response, and skin/wound repair. 8. KPV/alpha-MSH-derived peptide literature: anti-inflammatory signaling and NF-kB-related pathway modulation. 9. MOTS-C literature: mitochondrial-derived peptide biology, AMPK-linked metabolic homeostasis, and insulin-sensitivity research. 10. SS-31/elamipretide literature: cardiolipin interaction, mitochondrial membrane stabilization, and oxidative-stress modulation. 11. LL-37 literature: host-defense peptide biology, antimicrobial activity, wound vascularization, and immunomodulation. 12. Thymosin Alpha-1 literature: thymic immune modulation, T-cell signaling, dendritic-cell activity, and immune homeostasis. 13. For research-only compounds with limited human pharmacokinetic standardization, entries use conservative language and identify uncertainty rather than overstating clinical certainty.
Frequently asked questions
What is Melanotan 2 and how does it work?
Melanotan II is a melanocortin receptor agonist with activity at melanocortin receptors involved in melanogenesis, appetite signaling, libido, and central melanocortin pathways.
What is the half-life of Melanotan 2?
Melanotan 2: Short-to-moderate; context dependent. Human pharmacokinetics are not standardized. Treat exposure as short acting unless compound-specific data or formal formulation labeling indicates otherwise.
How is Melanotan 2 reconstituted for research?
Preferred reconstitution for the 10 mg vial is 2 mL BAC Water, giving 0.050 mg/unit. Always confirm concentration math before any use. Research use only.
Is Melanotan 2 FDA approved?
No. Melanotan 2 is an investigational research-use-only compound - not for human or animal consumption and not FDA approved.
Melanotan 2 product overview · Melanotan 2 cost · All research reference · Research guides
External references: Peptide (Wikipedia) · U.S. Food and Drug Administration